Structural Formula For Clopidogrel Bisulfate (Image 1)
Clopidogrel Tablet, Film Coated
Product Images NDC 0093-7314
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 0093-7314). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure-08.jpg (Image 10)
Image (Image 11)
This is a prescription drug that comes in the form of tablets in 75mg dosage. There is a Medication Guide that should be provided to each patient. The drug should be stored in a temperature range of 25°C (68°t0 77°F). It is manufactured in Israel for Teva Pharmaceuticals USA, Inc. There are 30 tablets in a pack. The lot and expiration date are not provided.*
Figure 1 (Image 2)
Figure 2 (Image 3)
The text provides a chart showing the cumulative event rate for cardiovascular death, myocardial infarction, and stroke for both a placebo group (taking aspirin) and a group taking clopidogrel with aspirin. The data is presented over a period of months and other standard therapies were implemented as necessary. The statistical significance between the two groups is indicated with p-value of 0.000008. No additional information is available.*
Figure-03a.jpg (Image 4)
This text appears to be a table of data related to a medical study or clinical trial. It includes information on gender, race, medical history, and treatment details for participants. However, there is not enough context to provide a clear description or analysis of the data.*
Figure-03b.jpg (Image 5)
Figure 4 (Image 6)
This appears to be a statistical report on the comparative effectiveness of a drug called Clopidogrel versus a Placebo in reducing the risk of death in a randomized trial. The report shows that 7% proportional risk reduction was recorded in patients treated with Clopidogrel compared to Placebo, with a p-value of 0.03. The report also shows the number of deaths before the first discharge in each group. The duration of the trial was up to 28 days.*
Figure 5 (Image 7)
The text appears to provide statistical data on the effectiveness of a drug compared to a placebo in reducing the risk of death, reinfarction, or stroke after a first discharge. The drug in question is clopidogrel and the placebo group had 2310 participants with a 10.1% event rate while the clopidogrel group had 2121 participants with a 9.2% event rate. The data shows a 0.79% proportional risk reduction (p=0.002). The graph shows the days since randomization up to 28 days.*
Figure-06.jpg (Image 8)
This appears to be a table with data related to a medical study, which likely examines the effectiveness of a medication (Clopidogrel) compared to a placebo. The data includes information on the subgroup of patients studied, including their gender, age at entry, hours since onset, blood pressure, and heart rate, as well as whether or not they were given a fibrinolytic agent. The table contains percentages for each subgroup that were treated with clopidogrel or a placebo, and odds ratios are provided for each year of the study.*
Figure 8 (Image 9)
The text contains a table with the cumulative event rate percentages for fatal or non-fatal vascular events for two types of medication, aspirin and clopidogrel, over a certain follow-up period of months. A statistically significant difference between the two medications is indicated (P=0.045). No additional information is available from the given text.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
